Intest Res Search

CLOSE


IBD

  • HOME
  • TOPICS
  • IBD
Inflammatory Bowel Diseases
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis
Intest Res. 2021;19(4):461-467.   Published online August 18, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi
Intest Res. 2021;19(4):448-460.   Published online August 18, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis
Saransh Jain, Divya Namdeo, Pabitra Sahu, Saurabh Kedia, Peush Sahni, Prasenjit Das, Raju Sharma, Vipin Gupta, Govind Makharia, Lalit Dar, Simon PL Travis, Vineet Ahuja
Intest Res. 2021;19(4):438-447.   Published online November 6, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, Kana Onishi, Takeshi Takasago, Masaki Wakai, Toshikatsu Naito, Kensuke Sasaki, Shigehiro Doi, Takao Masaki, Kazuaki Chayama
Intest Res. 2021;19(4):430-437.   Published online November 9, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Graphic abstract
Close layer
prev next
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
Intest Res. 2021;19(4):419-429.   Published online November 10, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, Takashi Hagiwara, Takeshi Kawaberi, Haruhiko Ogata, Toshiyuki Matsui, Mamoru Watanabe, Toshifumi Hibi
Intest Res. 2021;19(4):408-418.   Published online November 20, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy
Intest Res. 2021;19(4):398-407.   Published online November 20, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
Intest Res. 2021;19(4):386-397.   Published online December 1, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice
Yan Chen, Qiao Yu, Francis A. Farraye, Gursimran S. Kochhar, Charles N. Bernstein, Udayakumar Navaneethan, Kaicun Wu, Jie Zhong, David A. Schwartz, Hao Wu, Jing-Jing Zheng, Marietta Iacucci, Ravi P. Kiran, Bo Shen
Intest Res. 2021;19(3):332-340.   Published online June 2, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
Shin Ju Oh, Ga Young Shin, Hosim Soh, Jae Gon Lee, Jong Pil Im, Chang Soo Eun, Kang-Moon Lee, Dong Il Park, Dong Soo Han, Hyo Jong Kim, Chang Kyun Lee
Intest Res. 2021;19(3):323-331.   Published online August 18, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Incidence and risk factors for venous thrombosis among patients with inflammatory bowel disease in China: a multicenter retrospective study
Jing Liu, Xiang Gao, Ye Chen, Qiao Mei, Liangru Zhu, Jiaming Qian, Pinjin Hu, Qian Cao
Intest Res. 2021;19(3):313-322.   Published online November 25, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
Yasuo Suzuki, Takashi Hagiwara, Mariko Kobayashi, Kazuo Morita, Tomoyo Shimamoto, Toshifumi Hibi
Intest Res. 2021;19(3):301-312.   Published online August 20, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary MaterialGraphic abstract
Close layer
prev next
Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
Sanchit Sharma, Arti Gupta, Saurabh Kedia, Samagra Agarwal, Namrata Singh, Sandeep Goyal, Saransh Jain, Vipin Gupta, Pabitra Sahu, Sudheer Kumar Vuyyuru, Bhaskar Kante, Raju Sharma, Rajesh Panwar, Peush Sahni, Govind Makharia, Vineet Ahuja
Intest Res. 2021;19(3):291-300.   Published online May 26, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Trends of inflammatory bowel disease at a tertiary care center in northern India
Ajit Sood, Kirandeep Kaur, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Namita Bansal, Varun Mehta, Dharmatma Singh
Intest Res. 2021;19(3):282-290.   Published online August 18, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Prospective validation of CD4+CD25+FOXP3+ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease
Ritika Rampal, Saurabh Kedia, Mohamad Nahidul Wari, Deepak Madhu, Amit Kumar Singh, Veena Tiwari, V. Pratap Mouli, Srikant Mohta, Govind Makharia, Vineet Ahuja
Intest Res. 2021;19(2):232-238.   Published online May 8, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD

ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2021 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next